Prescient appoints oncology drug development veteran Dr Rosalind Wilson as chief medical officer
Experienced oncology drug development executive Dr Rosalind Wilson is joining Prescient Therapeutics Ltd (ASX:PTX) as chief medical...
Experienced oncology drug development executive Dr Rosalind Wilson is joining Prescient Therapeutics Ltd (ASX:PTX) as chief medical...
Prescient Therapeutics Ltd (ASX:PTX) has highlighted continued progress across its oncology development pipeline during the...
Prescient Therapeutics Ltd (ASX:PTX) is advancing enrolment in its Phase 2 clinical trial for lead asset...
Cancer remains one of the most formidable challenges in modern medicine — but it is...
Prescient Therapeutics Ltd (ASX: PTX) reported meaningful regulatory progress during the December 2025 quarter, with...
Prescient Therapeutics CEO James McDonnell talked with Proactive about the company’s clinical and regulatory progress...
Prescient Therapeutics Ltd (ASX: PTX) earlier this week received European authorisation to begin clinical trials...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) on Wednesday issued results for the June quarter highlighting the first...
In a sector where the right drug emerging at the right time can yield billions, Prescient...
Prescient Therapeutics Ltd CEO James McDonnell talked with Proactive about the company’s latest milestone —...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.